Hims & Hers Health expands with hormone replacement programs
Reading Time: 3 minutes
Hims & Hers focuses on hormones: New menopause and testosterone programs open up billion-dollar potential. Stock +15 %: Investors speculate on further price potential due to high short interest. The US telemedicine company Hims & Hers Health Inc. (NYSE: HIMS) has further expanded its position as a digital health provider. With two new initiatives – a menopause treatment for women and a testosterone program for men – the company is increasing its presence in the fast-growing hormone replacement therapy (HRT) market. The announcements...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
